Are There Significant Differences in 12-Month FVC Decline Between Pirfenidone and Nintedanib?

**STUDY DESIGN**
Post hoc analysis of CleanUP-IPF trial comparing patients with idiopathic pulmonary fibrosis (IPF)

Compared outcomes of patients receiving pirfenidone and those receiving nintedanib

**RESULTS**

**12 MONTHS:**
Nintedanib had a higher FVC, mean difference of 106 mL (95% CI, 34-178; P = .004)

**24 MONTHS:**
FVCs not different

No difference in survival or hospitalization

Patients with IPF who used nintedanib had a slower 12-month FVC decline than those who used pirfenidone in a post hoc analysis of the CleanUP-IPF trial.


Copyright © 2024 American College of Chest Physicians